Show Summary Details
Page of

(p. 327) Pharmacological Treatments for Unipolar Depression 

(p. 327) Pharmacological Treatments for Unipolar Depression
Chapter:
(p. 327) Pharmacological Treatments for Unipolar Depression
Author(s):

Stefania Prendes-Alvarez

, Alan F. Schatzberg

, and Charles B. Nemeroff

DOI:
10.1093/med:psych/9780199342211.003.0011
Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE (www.oxfordclinicalpsych.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 04 June 2020

Major depressive disorder is a chronic syndrome associated with high mortality (secondary to suicide and increased risk for heart disease, stroke, and other serious diseases). It is one of the most common medical disorders affecting adults in the world today. In the United States, the lifetime prevalence of major depression is 16.7% for adults. The average age of onset is 32 years, and women are 70% more likely to develop depression than men. Neither the core requisite symptoms for the diagnosis of a major depressive episode nor the required duration of at least 2 weeks has changed from DSM-IV to DSM-5. This chapter discusses the main issues surrounding the treatment of major depressive disorder, such as suicidality and goals of treatment, and provides information about all treatment options approved by the U.S. Food & Drug Administration. Drugs are categorized by their mechanisms of action.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.